PRPS2
Overview
PRPS2 (Phosphoribosyl Pyrophosphate Synthetase 2) encodes a rate-limiting enzyme in the de novo nucleotide biosynthesis pathway, catalyzing the conversion of ribose-5-phosphate to phosphoribosyl pyrophosphate (PRPP). Elevated nucleotide synthesis is a hallmark of rapidly proliferating cancer cells, making PRPS2 a candidate oncogenic driver in tumors with amplification or upregulation.
Alterations observed in the corpus
- Homozygous deletions in 3 cases (4.6%) in a WGS study of 65 triple-negative breast cancers; ranked 7th by driverNet driver scoring PMID:22495314
Cancer types (linked)
- Breast cancer (TNBC): recurrent homozygous deletions; high driverNet rank suggests functional relevance PMID:22495314
Co-occurrence and mutual exclusivity
- No co-occurrence or mutual exclusivity data reported in the corpus.
Therapeutic relevance
- As a nucleotide biosynthesis enzyme, PRPS2 may represent a metabolic vulnerability in TNBC; no clinical-stage therapeutics reported in the corpus.
Open questions
- The direction of effect (deletion vs. amplification) differs from the oncogenic role described in other contexts; functional characterization in TNBC is needed.
Sources
This page was processed by entity-page-writer on 2026-05-06.